2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Adil Daud, MD, clinical professor, Department of Medicine, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses challenges facing the treatment landscape of melanoma.
Adil Daud, MD, clinical professor, Department of Medicine, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses challenges facing the treatment landscape of melanoma.
One question that remains is which treatment patients should receive. According to Daud, there are advantages and disadvantages to each treatment option.
For most treatments, there will be at most 20% complete responses, but more research is needed to be done to increase that percentage. Potentially combining therapies could increase the response rates for patients, states Daud.